Pay in 4 interest-free payments of $6.79 Learn more
Ships within 48 hours · Estimated delivery Aug 5 - Aug 10
Originally developed and FDA-approved under the brand name Egrifta, Tesamorelin was intended to reduce visceral fat accumulation in HIV-positive patients with lipodystrophy
Once GSH is depleted, ROS and reactive nitrogen species escalate, leading to increased oxidative stress, mitochondrial dysfunction, and DNA damage
Others may need a longer period of consistent supplementation to see noticeable changes
In this case, less is more
Most are gastrointestinal and usually mild: Nausea (often improves after 24 weeks) Diarrhea or constipation Bloating or abdominal discomfort Reduced appetite (that one's the point) Fatigue in the first few weeks To minimize them: follow the titration schedule, eat smaller meals, go easy on greasy/high-fat foods, stay hydrated, and consider injecting at bedtime
US$ 20.84
US$ 26.64
US$ 27.17
US$ 26.62
US$ 26.58
US$ 25.44
US$ 26.54
US$ 25.14
US$ 23.75
